ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II
May 24, 2021BioXcel today announced that FDA has accepted for filing NDA for BXCL501,orally dissolving thin film formulation of dexmedetomidine,for the acute treatment of agitation associated with schizophrenia and Bipolar disorders I and II -
BioXcel’s agitation drug gets FDA Fast Track
December 29, 2018The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer’s and schizophrenia.
Pharma Sources Insight January 2025
